🚀 VC round data is live in beta, check it out!
Mayne Pharma Group Valuation Multiples
Discover revenue and EBITDA valuation multiples for Mayne Pharma Group and similar public comparables like Guerbet, Mersana Therapeutics, Journey Medical, Kalaris Therapeutics and more.
Mayne Pharma Group Overview
About Mayne Pharma Group
Mayne Pharma Group Ltd is a specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals It has a Forty-year track record of innovation and success in developing oral drug delivery systems. The Company's Business consists of three operating segments being International, Women’s Health and Dermatology. The Dermatologysegment distributes dermatology products (branded and generic) in the U.S. on a portfolio basis, The Women’s Health segment distributes branded women’s health products in the U.S. International’s segment revenue and gross profit are derived principally from the Australian manufacture and sale of branded and generic pharmaceutical products.
Founded
2005
HQ
Employees
450
Website
Sectors
Financials (LTM)
EV
$126M
Mayne Pharma Group Financials
Mayne Pharma Group reported last 12-month revenue of $267M and EBITDA of $31M.
In the same LTM period, Mayne Pharma Group generated $31M in EBITDA and had net loss of ($59M).
Revenue (LTM)
Mayne Pharma Group P&L
In the most recent fiscal year, Mayne Pharma Group reported revenue of $292M and EBITDA of $31M.
Mayne Pharma Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $267M | XXX | $292M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $176M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 60% | XXX | XXX | XXX |
| EBITDA | $31M | XXX | $31M | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 11% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (12%) | XXX | XXX | XXX |
| Net Profit | ($59M) | XXX | ($59M) | XXX | XXX | XXX |
| Net Margin | (22%) | XXX | (20%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Mayne Pharma Group Stock Performance
Mayne Pharma Group has current market cap of $146M, and enterprise value of $126M.
Market Cap Evolution
Mayne Pharma Group's stock price is $1.80.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $126M | $146M | 0.0% | XXX | XXX | XXX | $-0.73 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMayne Pharma Group Valuation Multiples
Mayne Pharma Group trades at 0.5x EV/Revenue multiple, and 4.1x EV/EBITDA.
EV / Revenue (LTM)
Mayne Pharma Group Financial Valuation Multiples
As of April 20, 2026, Mayne Pharma Group has market cap of $146M and EV of $126M.
Equity research analysts estimate Mayne Pharma Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Mayne Pharma Group has a P/E ratio of (2.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $146M | XXX | $146M | XXX | XXX | XXX |
| EV (current) | $126M | XXX | $126M | XXX | XXX | XXX |
| EV/Revenue | 0.5x | XXX | 0.4x | XXX | XXX | XXX |
| EV/EBITDA | 4.1x | XXX | 4.1x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (3.5x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 0.7x | XXX | XXX | XXX |
| P/E | (2.5x) | XXX | (2.5x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (15.3x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Mayne Pharma Group Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Mayne Pharma Group Margins & Growth Rates
Mayne Pharma Group's revenue in the last fiscal year grew by 2%.
Mayne Pharma Group's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.5M for the same period.
Mayne Pharma Group Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 2% | XXX | XXX | XXX |
| EBITDA Margin | 12% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (182%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 34% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 14% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 73% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Mayne Pharma Group Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Mayne Pharma Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Guerbet | XXX | XXX | XXX | XXX | XXX | XXX |
| Mersana Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Journey Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Kalaris Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| vTv Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Mayne Pharma Group M&A Activity
Mayne Pharma Group acquired XXX companies to date.
Last acquisition by Mayne Pharma Group was on XXXXXXXX, XXXXX. Mayne Pharma Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Mayne Pharma Group
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMayne Pharma Group Investment Activity
Mayne Pharma Group invested in XXX companies to date.
Mayne Pharma Group made its latest investment on XXXXXXXX, XXXXX. Mayne Pharma Group invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Mayne Pharma Group
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Mayne Pharma Group
| When was Mayne Pharma Group founded? | Mayne Pharma Group was founded in 2005. |
| Where is Mayne Pharma Group headquartered? | Mayne Pharma Group is headquartered in Australia. |
| How many employees does Mayne Pharma Group have? | As of today, Mayne Pharma Group has over 450 employees. |
| Who is the CEO of Mayne Pharma Group? | Mayne Pharma Group's CEO is Shawn Patrick O’Brien. |
| Is Mayne Pharma Group publicly listed? | Yes, Mayne Pharma Group is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of Mayne Pharma Group? | Mayne Pharma Group trades under MYX ticker. |
| When did Mayne Pharma Group go public? | Mayne Pharma Group went public in 2007. |
| Who are competitors of Mayne Pharma Group? | Mayne Pharma Group main competitors are Guerbet, Mersana Therapeutics, Journey Medical, Kalaris Therapeutics. |
| What is the current market cap of Mayne Pharma Group? | Mayne Pharma Group's current market cap is $146M. |
| What is the current revenue of Mayne Pharma Group? | Mayne Pharma Group's last 12 months revenue is $267M. |
| What is the current EV/Revenue multiple of Mayne Pharma Group? | Current revenue multiple of Mayne Pharma Group is 0.5x. |
| Is Mayne Pharma Group profitable? | Yes, Mayne Pharma Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Mayne Pharma Group? | Mayne Pharma Group's last 12 months EBITDA is $31M. |
| What is Mayne Pharma Group's EBITDA margin? | Mayne Pharma Group's last 12 months EBITDA margin is 12%. |
| What is the current EV/EBITDA multiple of Mayne Pharma Group? | Current EBITDA multiple of Mayne Pharma Group is 4.1x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.